Citius Pharmaceuticals Inc (CTXR) 13F Filing Data & Analysis (Q2 2026)

CTXR ranks #6558 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CTXR is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

43 institutions disclose a position in CTXR, but none treat it as a major bet — even Miller Financial Services LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Jane Street Group, LLC has added to its CTXR position for two straight quarters, increasing it by $60.3K to reach $74.3K today.

Susquehanna International Group, LLP has trimmed its CTXR position for two straight quarters, cutting it by $56.0K while still holding $7.1K.

CTXR reported a net loss of $58.2M over the trailing twelve months.

• Not yet profitable — net loss of $58.2M over the trailing twelve months
• Net income declined year over year, from -$42.1M to -$58.2M
• Operating cash flow was negative, using $26.6M in cash
• Current ratio of 0.62x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.79x equity — within a conventional range